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Bavachalcone and corylin are two major bioactive compounds isolated from Psoralea corylifolia L., which has been widely used
as traditional Chinese medicine for many years. As two antibiotic or anticancer drugs, bavachalcone and corylin are used in
combination with other drugs; thus it is necessary to evaluate potential pharmacokinetic herb-drug interactions (HDI) of the two
bioactive compounds. The aim of the present study was to compare the effects of liver UDP-glucuronosyltransferase (UGT) 1A1,
UGT1A3, UGT1A7, UGT1A8, UGT 1A10, and UGT2B4 inhibited by bavachalcone and corylin. 4-Methylumbelliferone (4-MU)
was used as a nonspecific “probe” substrate. Bavachalcone had stronger inhibition on UGT1A1 and UGT1A7 than corylin which
did not inhibit UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A10, and UGT2B4. Data fitting using Dixon and Lineweaver-Burk
plots demonstrated the noncompetitive inhibition of bavachalcone against UGT1A1 andUGT1A7-mediated 4-MU glucuronidation
reaction. The values of inhibition kinetic parameters (Ki) were 5.41𝜇M and 4.51 𝜇M for UGT1A1 and UGT1A7, respectively. The
results of present study suggested that there was a possibility of UGT1A1 and UGT1A7 inhibition-based herb-drug interaction
associated with bavachalcone and provided the basis for further in vivo studies to investigate the HDI potential between
bavachalcone and UGT substrates.
1. Introduction
Fructus Psoraleae, derived from dried ripe fruit of Psoralea
corylifolia L., has been commonly used as a traditional Chi-
nese medicine for warming kidney, activating yang, pro-
moting inspiration, and checking diarrhea [1]. It is listed in
both the Chinese Pharmacopoeia and the “List of Herbal
Materials that Can Be Used for Health Foods” under the
Law on Food Hygiene by State Food and Drug Administra-
tion [2]. Modern pharmacological and clinical studies have
shown that the extracts of Fructus Psoraleae possess different
biological activities, such as antioxidative [3], antimicro-
bial [4], anti-inflammatory, and antitumor activities [5]. As
antibiotic drug, Fructus Psoraleae attenuates lung inflamma-
tory responses and repairs the impairment of pneumonia
[6, 7]. In addition, Fructus Psoraleae was effective in the
treatment of lung carcinoma [8, 9].
As two major compounds isolated from the seed of Fruc-
tus Psoraleae, bavachalcone and corylin (Figure 1) are exten-
sively used in traditional medicine for the treatment of vari-
ous diseases. For example, bavachalcone was found to inhibit
osteoclastogenesis by interfering with the ERK and Akt sig-
naling pathways and inhibit the production of Gram-positive
bacteria [10, 11]. Similarly, corylin has strong antioxidant
activities and can be used to treat diabetic complications [12,
13]. Althoughmany biological and pharmacological activities
of bavachalcone and corylin have been studied, further phar-
macokinetic evaluation is conducted to understand their
clinical efficiency and safety. Drug metabolizing enzyme-
(DME-) catalyzed metabolic elimination significantly affects
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Figure 1: Structures of bavachalcone and corylin.
the concentration of drugs in plasma and therapeutic targets.
Inhibition of the DMEs’ activity can significantly increase the
exposure of drugs, possibly resulting in the adverse effects
of drugs, especially for the drugs with narrow therapeutic
index. Accordingly, the study of potential interaction between
herbal drugs and DME has received considerable attention
over the last years [14]. However, more attention had been
paid to cytochrome P450 (CYP450s) inhibition-based herb-
drug interaction (HDI) because CYP450 is involved in most
metabolisms of clinical drugs [15–17]. In contrast, other drug-
metabolizing enzymes, such as phase II conjugating enzymes,
have received less attention [18]. UGT-catalyzed glucuroni-
dation reactions are responsible for the metabolism of
approximately 35% of all drugs metabolized by phase II
enzymes [19]. UGTs, important biochemical factors of cel-
lular defense and detoxification, play an important role in
the metabolism of many clinical drugs or their phase I
metabolites [20].Therefore, inhibition of UGT-catalyzed glu-
curonidation reactions is the key reason for testing clini-
cal herb-drug interaction, because many xenobiotics have
been demonstrated to have inhibitory effects against UGTs-
catalyzed reactions, such as efavirenz [21], corydaline [22],
and glycyrrhetinic acid [23].
At present, no study has evaluated the inhibitory effects of
bavachalcone and corylin onUGT enzymes. In this study, the
effects of bavachalcone and corylin on the activity of sixmajor
human UGTs were examined using recombinant human
UGT supersomes to evaluate the possibility of bavachalcone
or corylin-drug interactions.
2. Materials and Methods
2.1. Materials. Bavachalcone and corylin were purchased
fromShifengCorp. (Shanghai, China), and their puritieswere
all above 98%. 4-Methylumbelliferone(4-MU), 4-methy-
lumbelliferone-𝛽-D-glucuronide(4-MUG), Tris-HCl, alame-
thicin, 7-hydroxycoumarin, and uridine 5󸀠-diphosphoglucu-
ronic acid (UDPGA) (trisodium salt) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Recombinant human
UGT supersomes (UGT1A1, UGT1A3, UGT1A7, UGT1A8,
UGT1A10, and UGT2B4) expressed in baculovirus-infected
insect cells were obtained from BD Gentest Corp. (Woburn,
MA, USA). Solvents and other reagents were of HPLC grade.
2.2. Inhibition of 4-MU Glucuronidation Assay. The inhibi-
tion of bavachalcone and corylin to UGT isoforms activity
was assessed using 4-MUas the nonspecific “probe” substrate.
Incubation and analytical conditions have been described
previously [24].Themixture (200 𝜇L total volume) contained
recombinant UGTs (final concentrations: 0.125, 0.05, 0.05,
0.025, 0.05, and 0.25mg/mL for UGT1A1, UGT1A3, UGT1A7,
UGT1A8, UGT1A10, and UGT2B4, resp.), 5mM UDPGA,
5mM MgCl
2
, 50mM Tris-HCl buffer (pH = 7.4), and 4-
MU in the absence or presence of different concentrations
of bavachalcone and corylin. The concentrations of 4-MU
were 100 𝜇M for UGT1A1, 1200𝜇M for UGT1A3, 30 𝜇M for
UGT1A7, 750𝜇M for UGT1A8, 80 𝜇M for UGT1A10, and
1200𝜇M for UGT2B4. Bavachalcone and corylin were dis-
solved in methanol and the final concentration of methanol
was 0.5% (v/v). After a 5min preincubation at 37∘C, the
UDPGA was added into the mixture to initiate the reac-
tion. Incubation time was 120min for UGT1A1, UGT1A3,
UGT1A10, and UGT2B4 and 30min for UGT1A7 and
UGT1A8. The reactions were quenched by adding 100𝜇L
acetonitrile with 7-hydroxycoumarin (100 𝜇M) as internal
standard. The mixture was centrifuged at 20,000×g for
20min and 20𝜇L of the supernatant was measured by
UFLC. For each concentration, two samples in parallel were
determined.
2.3. Ultrafast Liquid Chromatography (UFLC) Instrumenta-
tion and Conditions. The UFLC system (Shimadzu, Kyoto,
Japan) contained a SCL-20A system controller, two LC-
20AT pumps, a SIL-20A auto injector, and a SPD-20AV
UV detector. Chromatographic separation was carried out
using a Shim-pack XR-ODS column (2.0 × 75mm, 2.2 𝜇M,
Shimadzu) at flow rate of 0.5mL/min and UV detector at
320 nm. The mobile phase consisted of acetonitrile (A) and
H
2
O containing 0.5% (v/v) formic acid (B). The following
gradient condition was used: 0–4.00min, 95–50% B; 4.01–
7.00min, 5% B; and 7.01–10.00min, 95% B.
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Figure 2: The inhibitory effects of bavachalcone and corylin on
UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A10, and UGT2B4
isoforms. RecombinantUGT isoformswere used as enzyme sources.
4-MU was utilized as probe substrate. Incubation conditions were
described in the method section.
2.4. Data Fitting for the Determination of Inhibition Type and
Parameters (Ki). If UGTs were strongly inhibited, half inhi-
bition concentration (IC50) values were determined using
various concentrations of bavachalcone (100, 80, 60, 40, 20,
10, 5, 1, and 0 𝜇M for UGT1A1 and 50, 20, 10, 6, 5, 3, 1, 0.5, and
0 𝜇M for UGT1A7) with previously described methods [24].
Dixon and Lineweaver-Burk plots were adapted to determine
the inhibition type, and the second plot with the slopes
from the Lineweaver-Burk plot versus the concentrations of
components was utilized to calculate the Ki value.
3. Results
The retention time of 4-MU, 4-MUG, and 7-hydroxy-
coumarin were 2.68, 3.19, and 3.66min, respectively. As
shown in Figure 2, 100 𝜇M of bavachalcone inhibited the
activity of 4-MU glucuronidation by 91.2% (UGT1A1),
85.7% (UGT1A3), 94.0% (UGT1A7), 84.8% (1A8), 32.7%
(UGT1A10), and 87.7% (UGT2B4), respectively. 100 𝜇M of
corylin inhibited the activity of 4-MU glucuronidation by
80.8% (1A1), 79.2% (1A3), 74.4% (UGT1A7), 40.7% (1A8),
4.2% (UGT1A10), and 44.7% (UGT2B4), respectively. Fur-
thermore, kinetic analysis was performed which activity has
been inhibited by more than 90%. As shown in Figures
3(a) and 4(a), bavachalcone exhibited strongly concentra-
tion-dependent inhibitory behaviour against UGT1A1 and
UGT1A7-catalyzed 4-MU glucuronidation, with IC50 values
of 11.3 𝜇M for UGT1A1 and 3.6 𝜇M for UGT1A7, respectively.
Dixon plot (Figures 3(b) and 4(b)) and Lineweaver-Burk
plot (Figures 3(c) and 4(c)) showed that bavachalcone non-
competitively inhibited UGT1A1 and UGT1A7-mediated 4-
MU glucuronidation, and the Ki value was calculated to be
5.41 𝜇M for UGT1A1 and 4.51 𝜇M for UGT1A7 (Figures 3(d)
and 4(d)).
4. Discussion
It is necessary to determine how a potential drug inhibits or
induces the enzymes involved in drug metabolism because
these effects can lead to the molecular basis of interac-
tions with other concomitantly administered drugs and may
explain some toxic effects when a new drug is tested in vivo
or in vitro [25]. Cytochromes P450 (CYP450s) and UDP-
Glucuronosyltransferases (UGTs) are the major phase I and
phase II drug metabolism enzymes. Therefore, many studies
have focused on analyzing the effects of herbal compo-
nents on major human CYP450s and UGTs in human hep-
atocytes. Metabolic behavior and inhibitory potential of
Fructus Psoraleae have been attracting much attention of
researchers. Psoralen and isopsoralen have been proven to
have strong inhibitory potential against CYP1A2 [26]. It has
been clearly demonstrated that CYP1A2, CYP2C9, CYP2C19,
and CYP3A4 were the major CYP isoforms in liver micro-
somes (HLM) involved in the metabolism of bakuchiol and
CYP2C19 has been shown to have the highest metabolic rate
[27].
In this study, inhibitory effects of corylin and bavachal-
cone on six UGT isoforms were studied. Using a panel of
recombinant human UGT isoforms, we found no potent
inhibition of corylin against UGTs. In contrast, bavachalcone
has been demonstrated to have a noncompetitive inhibition
against UGT1A1 and UGT1A7 with the Ki values of 5.41𝜇M
and 4.51 𝜇M. UGT1A1 is responsible for the metabolism of
many endogenous and exogenous substrates, including 15%
drugs that have glucuronidation as a clearance mechanism of
the top 200 drugs in the United States in 2002 [28]. For exam-
ple, belinostat is an antitumor drug, and glucuronidation by
UGT1A1 is the dominant pathway of the metabolic disposi-
tion [29].The inhibition of UGT1A1 activity by bavachalcone
might significantly affect the elimination of belinostat and
then initiate the adverse effect when belinostat was coad-
ministered with bavachalcone to treat tumor. UGT1A7 is
an important phase II drug metabolism enzyme which is
present only in the esophagus, stomach, and lung. UGT1A7
was involved in themetabolismof SN-38 and SN-38G [30]. So
attention should be paid to bavachalcone-drug interactions
when bavachalcone is used together with drugs metabo-
lized by UGT1A1 or UGT1A7. The compounds containing
a hydroxyl group on the benzene ring are very susceptible
to metabolism catalyzed by phase II DMEs, including the
UGTs [31]. Bavachalcone contains three hydroxyl groups and
then corylin contains one hydroxyl group. This is possible
reason that bavachalcone had stronger inhibition against
UGT1A1 and UGT1A7 than corylin did. In addition, given
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Figure 3: Determination of inhibition kinetic type and parameters (Ki) of UGT1A1 inhibited by bavachalcone. (a) Bavachalcone exhibits
dose-dependent inhibition towards UGT1A1-catalyzed 4-MU glucuronidation. (b) Dixon plot of inhibitory effects of bavachalcone towards
recombinant UGT1A1-catalyzed 4-MU glucuronidation. (c) Lineweaver-Burk plot of inhibitory effects of bavachalcone towards recombinant
UGT1A1-catalyzed 4-MU glucuronidation. (d) Second plot of slopes from Lineweaver-Burk plot versus bavachalcone concentrations. Every
data point represents the mean of two replicates.
the fact that many in vivo factors (absorption, distribution,
metabolism, and excretion) could influence the in vitro-
in vivo extrapolation (IVIVE), further in vivo experiments
are required to evaluate the inhibition of drug-metabolizing
enzymes by bavachalcone.
In conclusion, we have demonstrated the strong inhib-
itory effect of bavachalcone against UGT1A1 and UGT1A7.
UGT1A1 and UGT1A7 are two important UGT isoforms
involved in the metabolism of many drugs. Herb-drug inter-
action may exist when bavachalcone is coadministered with
the clinical drugs which are able to be metabolized by
UGT1A1 and UGT1A7.
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Figure 4: Determination of inhibition kinetic type and parameters (Ki) of UGT1A7 inhibited by bavachalcone. (a) Bavachalcone exhibits
dose-dependent inhibition towards UGT1A7-catalyzed 4-MU glucuronidation. (b) Dixon plot of inhibitory effects of bavachalcone towards
recombinant UGT1A7-catalyzed 4-MU glucuronidation. (c) Lineweaver-Burk plot of inhibitory effects of bavachalcone towards recombinant
UGT1A7-catalyzed 4-MU glucuronidation. (d) Second plot of slopes from Lineweaver-Burk plot versus bavachalcone concentrations. Every
data point represents the mean of two replicates.
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